Autoimmune Disease Diagnostics Market Size & Share 2025 - 2034

Autoimmune Disease Diagnostics Market Size

The global autoimmune disease diagnostics market was valued at USD 5.7 billion in 2024. The market is expected to reach from USD 6.2 billion in 2025 to USD 11 billion in 2034, growing at a CAGR of 6.6% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the increasing prevalence of autoimmune diseases, growing awareness and screening programs, technological advancements in diagnostic tools, and increased healthcare expenditure, among other contributing factors.

Autoimmune disease diagnostics include medical tests and procedures performed to detect, identify, and monitor autoimmune disorders that result in the body's immune system erroneously attacking healthy tissues of the body. These diagnosis methods include blood tests, immunoassays, molecular tests, and imaging techniques directed at the detection of autoantibodies and inflammatory markers.
 

Leading players present in the autoimmune disease diagnostics market include Abbott, BIO-RAD, Roche, SIEMENS Healthineers, and Thermo Fisher Scientific. The companies hold a competitive edge via continuous product innovation, a presence throughout various regions in several international markets, and large investment in research and development.
 

The market has increased from USD 4.5 billion in 2021 and reached USD 5.3 billion in 2023, with the historic growth rate of 9.6%. The market growth was driven by the increasing healthcare expenditure, expanding geriatric population prone to autoimmune conditions, and rising adoption of personalized medicine and biomarker-based testing.
 

Moreover, the global prevalence of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis, continues to rise. According to the National Institutes of Health (NIH), as of 2023, approximately 24 million Americans have autoimmune disorders, up from 22 million in 2021.
 

The World Health Organization (WHO) reported in 2022 that rheumatoid arthritis affects 14 million people globally, with a 2.5% annual increase in new cases. Genetic predisposition, environmental triggers, and lifestyle changes contribute to increased incidence rates. The American Autoimmune Related Diseases Association (AARDA) documented a 4.1% increase in diagnosed cases between 2021 and 2023, driving demand for early and accurate diagnostic solutions.
 

Furthermore, increased awareness among patients and healthcare providers about the importance of early detection of autoimmune conditions is fueling diagnostic demand. Governments and health organizations are also running awareness campaigns and screening initiatives, leading to higher testing rates. This trend supports the wider adoption of advanced diagnostic tests.
 

Autoimmune Disease Diagnostics Market Trends

The market is growing considerably with the shift toward biomarker-based diagnostics, growing adoption of point-of-care testing (POCT), surging need for integration of artificial intelligence in healthcare, and rising demand for multiplex and automated systems, among other factors collectively driving industry growth.
 

• There has been an emphasis on identifying autoimmune diseases using specific biomarkers more precisely. Testing using biomarkers can help early detection, monitoring of the disease, and formulation of treatment strategies according to the patient. This trend strengthens the place of molecular and genetic testing in diagnostics.
   
• Further, the market shows increasing adoption of portable, rapid testing solutions for autoimmune conditions. According to the National Institutes of Health (NIH), the funding for autoimmune disease research increased from USD 1.1 billion in 2021 to USD 1.4 billion in 2023. The Centers for Medicare and Medicaid Services reported a 35% increase in point-of-care testing reimbursements between 2021 and 2023.
   
• Point-of-care testing (POCT) enables faster clinical decisions in both medical facilities and home settings, reducing dependence on central laboratories. The FDA approved 8 new POCT devices for autoimmune testing in 2022 and an additional 12 devices in 2023, reflecting the growing market demand. This shift improves patient access to diagnostic services and enhances testing convenience.
   
• Additionally, the increasing use of diagnostics to tailor treatment plans for autoimmune patients is becoming a key market trend. Genetic profiling and individualized testing approaches help in predicting patient response to therapies. This trend is fostering collaborations between diagnostic companies and pharmaceutical firms, thereby sustaining market growth.
   

Autoimmune Disease Diagnostics Market Analysis

Based on the product, the autoimmune disease diagnostics market is segmented into reagents and consumables and instruments. The reagents and consumables segment has asserted its dominance in the market by securing a significant market share of 67% in 2024 owing to their recurring demand in routine testing and the rising adoption of advanced assay kits for faster, accurate, and reliable diagnostics. The segment is expected to exceed USD 7.5 billion by 2034, growing at a CAGR of 6.9% during the forecast period.
 

On the other hand, the instruments segment is expected to grow with a CAGR of 6%. The growth of this segment is driven by the technological advancements in immunoassay and molecular platforms, along with increasing lab automation needs to enhance efficiency and accuracy in testing.
 

• The reagents and consumables segment continues to dominate the market. With the increasing global burden of autoimmune diseases, there has been a substantial rise in the number of diagnostic tests being performed. Each diagnostic test uses reagents and consumables like antibodies, assay kits, buffers, etc., creating a recurring demand. The use of consumables is hence continuous, as instances where tests are required are many, often for the purpose of monitoring, with multiple tests involved over a span of time.
   
• Technologies like ELISA, immunofluorescence assays, and multiplex immunoassays rely heavily on high-quality reagents and consumables. As labs adopt more sophisticated and automated diagnostic systems, the demand for compatible kits and reagents increases. This dependence ensures a steady market for consumable products.
   
• Moreover, the expansion of specialized diagnostic laboratories and hospital-based testing facilities directly boosts the consumption of reagents. Large testing volumes in centralized labs require consistent supplies of consumables for routine operations. This expansion strengthens the supply chain demand for manufacturers.
   
• The instruments segment held a revenue of USD 1.9 billion in 2024, with projections indicating a steady expansion at 6% CAGR from 2025 to 2034. The segmental growth is driven by the rising demand for high-throughput systems to handle increasing test volumes. Integration of digital platforms with diagnostic instruments is enabling real-time data analysis and improved workflow efficiency.
   
• Growing adoption of multiplexing technologies is allowing simultaneous detection of multiple autoimmune markers. In addition, the shift toward precision medicine is fueling demand for advanced instruments that deliver highly sensitive and specific results.
   

Based on disease type, the autoimmune disease diagnostics market is segmented into localized autoimmune disease and systemic autoimmune disease. The localized autoimmune disease segment is further bifurcated into Type 1 diabetes, inflammatory bowel disease, thyroid, and other localized autoimmune diseases. The localized autoimmune disease segment dominated the market in 2024, accounting for USD 4 billion and is anticipated to grow at a CAGR of 6.4% during the forecast period.
 

• Localized autoimmune diseases, including Type 1 diabetes, inflammatory bowel disease, and thyroid, are now being found in increasing numbers all over the world. These disorders target particular organs and lead to long-term complications if not detected early. This higher rate of occurrence creates a demand for highly precise diagnostic methods that can be carried out on organ-specific bases.
   
• Most of these diseases run silently without manifestations until late in the process and thus require early intervention. Diagnostic tests such as autoantibody panels and molecular assays act as early detectors of the disease markers. This requirement for early detection is forcing healthcare providers to opt for more selective diagnostic options.
   
• Moreover, innovations such as next-generation sequencing, advanced ELISA kits, and biomarker-based immunoassays are enhancing the accuracy of localized autoimmune diagnostics. These advancements allow simultaneous detection of multiple disease-specific markers. The availability of such tailored technologies is expanding the adoption of specialized diagnostic platforms.
   
• The systemic autoimmune disease segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 7% over the forecast period. The growth of the segment is driven by the rising prevalence of conditions like lupus, rheumatoid arthritis, and Sjögren’s syndrome that require frequent monitoring. The complexity of these diseases increases demand for multi-marker panels and comprehensive testing solutions.
   
• Advances in biomarker discovery are enabling earlier detection and better disease stratification in systemic conditions. Additionally, growing clinical adoption of personalized treatment approaches is fueling demand for accurate systemic autoimmune diagnostics.
   

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibody tests, autoantibody tests, complete blood count (CBC), C-reactive protein (CRP), urinalysis, and other test types. The antinuclear antibody tests segment dominated the market in 2024, accounting for USD 2.5 billion and is anticipated to grow at a CAGR of 7.1% during the forecast period.
 

• Antinuclear antibody (ANA) tests are crucial because they help recognize autoimmune activity before the actual severe symptoms appear. They can also help the doctor monitor disease progression and see if treatment is working. Therefore, with their double role in both diagnosis and monitoring, routine use in clinical practice is promoted, thus pushing the market demand.
   
• Further, with the clinical laboratories, hospital diagnostic centers, and special autoimmune clinics expanding, more access to ANA tests is being created. Centralized laboratories combine the higher throughput with automated platforms that simplify testing. This, in turn, creates a stable and scalable demand for ANA reagents and kits with improved infrastructure.
   
• The autoantibody tests segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 6.8% over the forecast period. The growth of the segment is driven by their critical role in the early and accurate diagnosis of various autoimmune disorders. Increasing clinical reliance on these tests for monitoring disease progression and guiding personalized treatment plans further boosts adoption. Moreover, continuous improvements in assay sensitivity and specificity are enhancing their reliability, making them a preferred choice in both routine and specialized diagnostic settings.
   
• The complete blood count (CBC) segment held a revenue of USD 487.5 million in 2024, with projections indicating a steady expansion at 5.9% CAGR from 2025 to 2034. The segmental growth is driven by their essential role in routine screening and monitoring of autoimmune conditions, providing critical insights into blood cell abnormalities. Their wide availability, low cost, and quick turnaround make CBC a fundamental and highly utilized diagnostic tool in clinical practice.
   
• The C-reactive protein (CRP) segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 6.3% over the forecast period. The growth of the segment is driven by their ability to rapidly indicate inflammation levels, aiding in the diagnosis and monitoring of autoimmune disease activity. Growing clinical reliance on CRP for assessing treatment efficacy and detecting disease flares further supports its widespread adoption.
   
• The urinalysis segment held a revenue of USD 150.5 million in 2024, with projections indicating a steady expansion at 5.2% CAGR from 2025 to 2034. The segmental growth is driven by its non-invasive approach to detect kidney involvement and monitor disease progression in autoimmune disorders. Its cost-effectiveness and ease of integration into routine diagnostic workflows make it a widely adopted tool in clinical settings.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the autoimmune disease diagnostics market is classified into hospitals, diagnostics centers, and other end users. The hospitals segment dominated the market with a revenue share of 53.2% in 2024 and is expected to reach USD 5.8 billion within the forecast period.
 

• Hospitals are witnessing a growing number of patients with autoimmune conditions due to rising prevalence and better disease awareness. This patient influx drives demand for in-house diagnostic services. Hospitals prefer comprehensive testing facilities to provide timely diagnosis and treatment, increasing investment in autoimmune diagnostics.
   
• Additionally, many hospitals are establishing dedicated immunology and rheumatology departments to manage complex autoimmune diseases. These specialized units require advanced diagnostic tools, including molecular assays, immunoassays, and autoantibody panels. The expansion of such departments boosts procurement of diagnostic instruments, reagents, and consumables.
   
• The diagnostics centers segment held a revenue of USD 2.3 billion in 2024, with projections indicating a steady expansion at 6.9% CAGR from 2025 to 2034. The segmental growth is driven by the increasing demand for specialized autoimmune testing and the convenience of centralized, comprehensive services. Expansion of healthcare infrastructure and the rising number of outpatient testing facilities are boosting accessibility.
   
• Advanced laboratory capabilities and the adoption of automated and multiplex testing systems enhance efficiency and accuracy. Additionally, patient preference for one-stop diagnostic solutions supports the growing role of diagnostics centers in autoimmune disease management.
   

North America Autoimmune Disease Diagnostics Market
 

North America dominated the market with the highest market share of 36.6% in 2024.
 

• The U.S. market was valued at USD 1.6 billion and USD 1.7 billion in 2021 and 2022, respectively. The market size reached USD 2 billion in 2024, growing from USD 1.8 billion in 2023, and is anticipated to grow at a CAGR of 5.8% between 2025 to 2034.
   
• North America has one of the highest rates of autoimmune disorders in the world. These include lupus, rheumatoid arthritis, multiple sclerosis, and Type 1 diabetes. The National Institutes of Health (NIH) reported that about 24 million Americans had autoimmune disorders in 2022, which is up from 22 million in 2021.
   
• The Centers for Disease Control and Prevention (CDC) showed that Type 1 diabetes cases rose by 2.3% each year from 2021 to 2023. The American Autoimmune Related Diseases Association (AARDA) predicts that by 2024, one in 12 Americans will have an autoimmune condition.
   
• The rising number of diagnosed cases generates significant demand for diagnostic tests. The need for early detection and continuous monitoring of these conditions sustains the growth of the autoimmune diagnostics market.
   
• Additionally, the region boasts highly developed hospitals, diagnostic laboratories, and research centers equipped with state-of-the-art technologies. Availability of automated immunoassays, ELISA platforms, and multiplex testing systems encourages the adoption of sophisticated autoimmune diagnostics. This robust infrastructure supports rapid market growth.
  
   

Europe Autoimmune Disease Diagnostics Market
 

Europe market accounted for USD 1.7 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• European countries that have public healthcare value preventive care and routine testing. In 2023, the European Union invested USD 6.2 billion toward healthcare initiatives, and 23% of that was devoted to diagnostic testing programs.
   
• The UK National Health Service reported a 15% rise in autoimmune diagnostic tests from 2021 to 2023, performing over 2.8 million tests each year. In Germany, public insurance coverage for autoimmune diagnostics increased by 18% in 2022, resulting in a 27% jump in test volumes across 1,200 diagnostic centers.
   
• Patient organizations and awareness campaigns in Europe are educating the public on autoimmune disorders and the importance of early diagnosis. This heightened awareness leads to more patients seeking testing and regular monitoring, further boosting demand for diagnostic services.
   
• Additionally, the region has seen an expansion of specialized immunology and autoimmune diagnostic labs, offering advanced services such as multiplex testing and molecular diagnostics. These labs complement hospital services, driving demand for reagents, consumables, and testing platforms. The proliferation of such centers supports market growth.
  
   

Asia Pacific Autoimmune Disease Diagnostics Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 7.8% during the analysis timeframe.
 

• The Asia Pacific region's large population experiences increasing cases of autoimmune diseases, with approximately 50 million cases reported in 2023, according to the Asia Pacific League of Associations for Rheumatology (APLAR). In China alone, the prevalence of autoimmune diseases increased by 12.5% between 2021 and 2023, as reported by the Chinese Medical Association.
   
• In addition, the data from the Japanese Ministry of Health shows that facilities for autoimmune testing grew by 15% from 2021 to 2024, which improved access to healthcare. In India, government programs led to a 25% increase in awareness campaigns for autoimmune diseases during 2022-2023, resulting in a 30% rise in testing volumes.
   
• Additionally, healthcare providers in the Asia Pacific region are using more modern diagnostic technologies, including ELISA, multiplex immunoassays, and automated platforms. Access to these technologies improves accuracy, shortens turnaround time, and promotes wider use of autoimmune testing in hospitals and laboratories.
  
   

Latin America Autoimmune Disease Diagnostics Market
 

The Latin America market is experiencing robust growth over the analysis timeframe.
 

• The regional growth is driven by the rising prevalence of autoimmune disorders, particularly rheumatoid arthritis, lupus, and multiple sclerosis, increasing the demand for accurate diagnostic solutions. Growing awareness among patients and healthcare professionals is encouraging early diagnosis and routine testing.
   
• Expansion of healthcare infrastructure, including specialized diagnostic laboratories and hospitals, is improving accessibility across urban and semi-urban regions. Government initiatives and public health programs are supporting autoimmune disease screening and research activities. Increasing investments by global and regional diagnostic companies are enhancing the availability of advanced assay kits and instruments.
   
• The adoption of automated and multiplex testing technologies is improving diagnostic efficiency and reliability. Furthermore, rising disposable income and growing insurance coverage are enabling more patients to access and afford autoimmune diagnostic services, contributing to market growth.
  
   

Middle East and Africa Autoimmune Disease Diagnostics Market
 

The Middle East and Africa market is experiencing robust growth over the analysis timeframe.
 

• The regional growth is driven by the increasing prevalence of autoimmune disorders due to genetic, environmental, and lifestyle factors. Rising awareness among healthcare professionals and patients is promoting early diagnosis and timely intervention.
   
• Expansion of healthcare infrastructure, including specialized diagnostic centers and hospital laboratories, is enhancing access to advanced testing. Supportive government initiatives and funding for healthcare and research are encouraging the adoption of innovative diagnostic technologies. Increasing presence of global diagnostic companies is improving the availability of high-quality reagents, consumables, and instruments.
   
• Adoption of automated and multiplex testing systems is boosting efficiency and accuracy in autoimmune diagnostics. Additionally, growing medical tourism in certain MEA countries is driving demand for state-of-the-art diagnostic services and comprehensive autoimmune testing.
   

Autoimmune Disease Diagnostics Market Share

The market is highly competitive, characterized by the presence of several global and regional players offering a wide range of instruments, reagents, and assay kits. Companies are focusing on technological innovations, such as multiplex assays, molecular diagnostics, and AI-driven platforms, to enhance diagnostic accuracy and efficiency. Strategic initiatives like mergers, acquisitions, partnerships, and regional expansions are commonly employed to strengthen market presence and broaden product portfolios.
 

Key players include Abbott, BIO-RAD, Roche, SIEMENS Healthineers, and Thermo Fisher Scientific, collectively accounting for 29.4% of the total market share. These companies maintain a competitive edge through strong research and development investments, advanced diagnostic platforms, and extensive distribution networks. Continuous product launches and collaborations with research institutions further enable them to cater to the growing demand for precise and rapid autoimmune disease diagnostics globally.
 

Autoimmune Disease Diagnostics Market Companies

Few of the prominent players operating in the autoimmune disease diagnostics industry include:

• Abbott
• BIOMERIEUX
• BIO-RAD
• DIAsource
• Euroimmun
• GRIFOLS
• Hemagen Diagnostics
• Inova Diagnostics (Werfen)
• Labcorp
• Quest Diagnostics
• Revvity
• Roche
• SIEMENS Healthineers
• Thermo Fisher Scientific
• Trinity Biotech
   
• Roche

Roche, leading the autoimmune disease diagnostics market with an 11.2% share in 2024, offers a comprehensive portfolio of immunoassays and molecular diagnostics for autoimmune diseases, with high sensitivity and specificity. Its advanced cobas systems enable automated, high-throughput testing, ensuring faster and reliable results across clinical laboratories globally.
 

• Abbott

Abbott leverages its ARCHITECT and Alinity platforms to provide accurate and scalable autoimmune diagnostics. The company’s strong global distribution network and focus on cost-effective solutions enhance accessibility and adoption in diverse healthcare settings.
 

• SIEMENS Healthineers

Siemens Healthineers stands out with its integrated laboratory solutions and automation technologies that streamline workflow and improve efficiency. Its innovative immunoassay and multiplex testing platforms enable rapid, precise detection of multiple autoimmune markers in a single test.
 

Autoimmune Disease Diagnostics Industry News:

• In June 2022, Quotient Limited announced that it had entered into an agreement with Theradiag to advance autoimmune diagnostics using Quotient’s MosaiQ platform. Theradiag supplied autoimmune reagents and multi-constituent quality controls for developing autoimmune microarrays on the MosaiQ solution. This collaboration strengthens the market by enabling more precise and efficient diagnostics for connective tissue diseases (CTD).
   
• In May 2022, Thermo Fisher Scientific announced the availability of the Phadia 2500+ Instrument in the U.S. for autoimmune testing. This device aids in the diagnosis of autoimmune diseases, including celiac disease, rheumatoid arthritis, autoimmune liver disease, and autoimmune thyroid disease, among others. This strategic launch helped the company gain business revenue along with an enhanced customer base.
   
• In May 2021, Labcorp acquired select assets and intellectual property from Myriad Genetics’ autoimmune business, including the Vectra RA assay. Over one million Vectra tests had been completed since its 2010 launch, with much of the testing handled by Labcorp. This move strengthens Labcorp’s autoimmune diagnostics portfolio and expands its market presence.
   

The autoimmune disease diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Reagents and consumables
• Instruments

Market, By Disease Type

• Localized autoimmune disease
  • Type 1 diabetes
  • Inflammatory bowel disease
  • Thyroid
  • Other localized autoimmune diseases 
• Systemic autoimmune disease
  • Rheumatoid arthritis
  • Systemic lupus erythematosus (SLE)
  • Multiple sclerosis
  • Psoriasis
  • Other systemic autoimmune diseases

Market, By Test Type

• Antinuclear antibody tests
• Autoantibody tests
• Complete blood count (CBC)
• C-reactive protein (CRP)
• Urinalysis
• Other test types

Market, By End Use

• Hospitals
• Diagnostics centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE